TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27133000
Drug: Standard-of-care therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care therapy without videos
Study: 25412614
Drug: Medical Treatment
Normalized name: Medical air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Treatment Only (MTO)
Study: 19938897
Drug: Fampridine-SR (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fampridine-SR (10 mg twice daily)
Study: 19938897
Drug: Fampridine-SR (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fampridine-SR (30 mg twice daily)
Study: 19938897
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg on treatment day 5)
Study: 17122715
Drug: General antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: General antidepressant requests
Study: 17122715
Drug: Brand-specific antidepressant
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand-specific antidepressant requests
Study: 17122715
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication requests
Study: 15301041
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate (TU) 40 mg daily
Study: 15301041
Drug: Intramuscular depot
Normalized name: Primoteston Depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular depot sustanon 50 (SUS), 4 weekly
Study: 30919407
Drug: ASN002 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASN002 20 mg
Study: 30919407
Drug: ASN002 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASN002 40 mg
Study: 30919407
Drug: ASN002 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASN002 80 mg
Study: 25305090
Drug: Ticagrelor 180
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180 mg loading dose (LD)/90 mg twice-daily maintenance dose (MD)
Study: 25305090
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg LD/75 mg once-daily MD
Study: 29954374
Drug: Low tocotrienol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tocotrienol (430 mg tocotrienol/day from DeltaGold 70 containing 300 mg tocotrienol)
Study: 29954374
Drug: High tocotrienol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High tocotrienol (860 mg tocotrienol/day from DeltaGold 70 containing 600 mg tocotrienol)
Study: 27363723
Drug: Steroid-releasing implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-releasing implant
Study: 17216745
Drug: Phenylpropanolamine (PPA)
DrugBank: Phenylpropanolamine (DB00397)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylpropanolamine (PPA) 50 mg twice daily for seven days
Study: 12628617
Drug: Piracetam (4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (4.8 g/day)
Study: 12628617
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba (120 mg/day)
Study: 9398896
Drug: Eradication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication therapy (antibiotics)
Study: 1593661
Drug: Enriched tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enriched tapering and aftercare assistance program (available to 58 clients)
Study: 6379122
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (MVPP)
Study: 6379122
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by radiotherapy (MVPP + radiotherapy)
Study: 28429147
Drug: Modafinil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (200 mg/day for 15 days)
Study: 28929697
Drug: Berberine 300
Normalized name: berberine
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberine 300 mg (tid) in addition to general therapy
Study: 28929697
Drug: General therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: General therapy according to the latest guidelines
Study: 22112606
Drug: Ritonavir‐boosted protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir‐boosted protease inhibitor (PI/r)
Study: 19528867
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment - dynamic stretches only
Study: 17558827
Drug: Bupropion 300
Normalized name: buPROPion 300 mg/24 hours oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion 300 mg/day with Cognitive Behavioral Therapy (CBT)
Study: 17558827
Drug: Bupropion 300
Normalized name: buPROPion 300 mg/24 hours oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion 300 mg/day with Supportive Therapy (ST)
Study: 17558827
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with Cognitive Behavioral Therapy (CBT)
Study: 17558827
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with Supportive Therapy (ST)
Study: 15366592
Drug: Integrative Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative Chinese and Western medicine (ICWM) with Kangmin Xiaoban Yin for 7-10 days
Study: 15366592
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Western routine therapy)
Study: 9074535
Drug: Metoprolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (50 mg orally 12 hr and 1 hr before the study)
Study: 9074535
Drug: Metoprolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (50 mg orally 12 hr and 1 hr before the study) with dipyridamole
Study: 22541840
Drug: Losartan Potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan Potassium Tablets 50 mg
Study: 22541840
Drug: Cozaar® Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cozaar® Tablets 50 mg
Study: 17526461
Drug: MAOx (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAOx (1.2 g)
Study: 12948801
Drug: Hypnotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnotic treatment (zolpidem, triazolam, zopiclone, brotizolam)
Study: 9356866
Drug: silymarin (210
Approvals — FDA: no, EMA: no, PMDA: no
Description: silymarin (210 mg/day)
Study: 9356866
Drug: no drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: no drug treatment (control group)
Study: 8222746
Drug: Ciprofloxacin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (2 mg/ml) ear drops twice daily for 7 days
Study: 8222746
Drug: Combined antibiotic
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined antibiotic (oxytetracycline 5 mg/ml, polymyxin B 10,000 units/ml, hydrocortisone 15 mg/ml) ear drops twice daily for 7 days
Study: 3511930
Drug: Metoprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (200 mg slow release tablets once daily for at least 2 weeks, plus 15 mg i.v. shortly before anaesthesia)
Study: 3511930
Drug: Placebo (tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (tablets and saline)
Study: 22588156
Drug: Tasisulam sodium
Normalized name: Tasisulam
DrugBank: Tasisulam (DB11941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tasisulam sodium (LY573636 sodium) administered as a 2-hour infusion every 21 days at a Cmax target dose of 420 µg/ml
Study: 22588156
Drug: Tasisulam sodium
Normalized name: Tasisulam
DrugBank: Tasisulam (DB11941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tasisulam sodium (LY573636 sodium) administered at a lower Cmax target dose of 380 µg/ml
Study: 18716159
Drug: 50 mg/d
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/d quercetin for 2 weeks
Study: 18716159
Drug: 100 mg/d
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/d quercetin for 2 weeks
Study: 18716159
Drug: 150 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/d quercetin for 2 weeks
Study: 15943544
Drug: Transdermal methylphenidate
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal methylphenidate (MPH) 12.5 cm²
Study: 15943544
Drug: Transdermal methylphenidate
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal methylphenidate (MPH) 25.0 cm²
Study: 15943544
Drug: Transdermal methylphenidate
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal methylphenidate (MPH) 37.5 cm²
Study: 15943544
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (MPH + BMOD)
Study: 12801361
Drug: Miconazole (Daktarin(R)
Normalized name: Miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole (Daktarin(R) gel oral)
Study: 12801361
Drug: Gel of
Normalized name: ZINC OXIDE 160 mg in 1 g TOPICAL OINTMENT [Angel of mine Diaper Rash]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel of Punica granatum Linné (pomegranate)
Study: 10591258
Drug: Contact laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contact laser ablation of the prostate (CLAP) using Nd:YAG laser treatment
Study: 8915274
Drug: Fast ingestion
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast ingestion group with 20 mg of oral metoclopramide
Study: 8915274
Drug: Standard ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ingestion group without additional drugs
Study: 30744092
Drug: Olive leaf
Normalized name: OLIVE LEAF
DrugBank: Olea europaea leaf (DB14745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive leaf extract (OLE) supplementation (100 mg oleuropein equivalent to 20 g of olive leaf) for nine weeks.
Study: 28654312
Drug: T'ai chi
Approvals — FDA: no, EMA: no, PMDA: no
Description: T'ai chi combined with health education twice weekly for 12 weeks
Study: 19887279
Drug: Sugammadex (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex (2 mg/kg after obtaining 2 responses, 4 mg/kg with post‐tetanic count between 1 and 3 responses, 12 to 16 mg/kg for rescue reversal)
Study: 17383057
Drug: MF59-adjuvanted subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted subunit vaccine (Sub/MF59)
Study: 12708121
Drug: Pranayam training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranayam training (nadishuddhi, mukh-bhastrika, pranav and savitri pranayams) for 20 minutes daily for 3 months
Study: 9892329
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg warfarin
Study: 30946887
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment (control)
Study: 28029326
Drug: O-DHAP (Ofatumumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: O-DHAP (Ofatumumab 1,000 mg)
Study: 28029326
Drug: R-DHAP (Rituximab
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-DHAP (Rituximab 375 mg/m2)
Study: 26392096
Drug: Short-course radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course radiotherapy (25 Gy in five daily fractions over 1 week)
Study: 26392096
Drug: Commonly used
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commonly used radiotherapy (40 Gy in 15 daily fractions over 3 weeks)
Study: 21765361
Drug: Standard amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard amino acid intake (1.5 g · kg(‐1) · day(‐1))
Study: 21765361
Drug: High amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High amino acid intake (3.0 g · kg(‐1) · day(‐1))
Study: 19357135
Drug: 1 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg/day low molecular weight heparin (LMWH)
Study: 1928019
Drug: Relapse Prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relapse Prevention Therapy (RPT) among severe users
Study: 7095565
Drug: Aspirin (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (two tablets four times a day for 24 hours)
Study: 7095565
Drug: Bufferin (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bufferin (two tablets four times a day for 24 hours)
Study: 7095565
Drug: Paracetamol (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (two tablets four times a day for 24 hours)
Study: 7095565
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two tablets four times a day for 24 hours)
Study: 29794581
Drug: Both TDR
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both TDR and nonoperative treatment
Study: 27078151
Drug: CHO+PROT (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO+PROT (0.8 g carbohydrate + 0.4 g protein·kg(‐1)·h(‐1))
Study: 27078151
Drug: CHO (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO (1.2 g carbohydrate·kg(‐1)·h(‐1))
Study: 22445212
Drug: Medication (fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (fluoxetine or venlafaxine)
Study: 1828415
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg etodolac twice daily (n = 112)
Study: 1828415
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg piroxicam once daily (n = 108)
Study: 31601842
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of pomegranate extract (PomX)
Study: 26059264
Drug: Guideline-concordant prescribing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-concordant prescribing of ACE-inhibitors/statins in early clinics
Study: 19139736
Drug: Intra-BM injection
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intra-BM injection (IBMI) of one UCB unit
Study: 19139736
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) injection of one UCB unit
Study: 11509937
Drug: 100 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/kg intravenous immunoglobulin
Study: 11509937
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of intravenous immunoglobulin
Study: 11509937
Drug: 250 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/kg and 500 mg/kg intravenous immunoglobulin
Study: 7804585
Drug: Topical ibuprofen
Normalized name: ibuprofen Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ibuprofen cream
Study: 3243930
Drug: Transdermally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermally administered scopolamine (TTS-scopolamine) with acute alcohol intake (BAC 80 mg/dL)
Study: 3243930
Drug: Transdermally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermally administered scopolamine (TTS-scopolamine) with acute alcohol intake (BAC 130 mg/dL)
Study: 3243930
Drug: Transdermally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermally administered scopolamine (TTS-scopolamine)
Study: 25107900
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg IVT-AFL every 4 weeks (0.5q4)
Study: 25107900
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg IVT-AFL every 4 weeks (2q4)
Study: 25107900
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg IVT-AFL every 8 weeks (2q8)
Study: 25107900
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ranibizumab every 4 weeks (Rq4)
Study: 24005242
Drug: Cognitive-behavioral prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral prevention (CBP) program consisting of 8 weekly 90-minute group sessions followed by 6 monthly continuation sessions.
Study: 21439275
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid and vitamin B administration for 3 months in nondiabetic group
Study: 21439275
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid and vitamin B administration for 3 months in diabetic group
Study: 18513835
Drug: Oral bolus
Normalized name: phenylbutazone 1000 MG Oral Bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bolus (OB) feeding
Study: 10735611
Drug: Terlipressin (2mg/iv
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (2mg/iv injection)
Study: 1477649
Drug: rhGM‐CSF administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGM‐CSF administered subcutaneously (s.c.)
Study: 29465250
Drug: Esomeprazole intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole intravenous bolus every 12 hours for 72 hours with second look endoscopy
Study: 29465250
Drug: Continuous high
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous high dose esomeprazole infusion for 72 hours
Study: 25085607
Drug: High-level endurance
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-level endurance training combined with cognitive-behavioural therapy (CBT)
Study: 25085607
Drug: Low-level exercise
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level exercise combined with cognitive-behavioural therapy (CBT)
Study: 17345071
Drug: Levodopa 25
Normalized name: levodopa 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa 25 mg
Study: 17345071
Drug: Levodopa 50
Normalized name: levodopa 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa 50 mg
Study: 17345071
Drug: Levodopa 250
Normalized name: levodopa 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa 250 mg
Study: 17345071
Drug: Levodopa 100
Normalized name: levodopa 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa 100 mg (1 x 100 mg)
Study: 17345071
Drug: Levodopa 100
Normalized name: levodopa 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa 100 mg (3 x 100 mg over 3 hours)
Study: 14699490
Drug: Adefovir 10
Normalized name: adefovir 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adefovir 10 mg daily + Lamivudine
Study: 28878437
Drug: Intensive health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive health guidance using IoT devices (measuring daily activity, body weight, and blood pressure)
Study: 24655119
Drug: IV alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV alcohol infusion to attain and clamp the breath alcohol concentration (BrAC) at 50 mg%
Study: 2125864
Drug: Electric acupuncture
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electric acupuncture stimulation (Hegu and Neiguan) with intravenous Pethedine (1.3 mg/kg)
Study: 2125864
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 5% Glucose during operation
Study: 30670438
Drug: Rifapentine 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifapentine 1,200 mg once weekly
Study: 30670438
Drug: Rifapentine 900
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifapentine 900 mg twice weekly
Study: 30670438
Drug: Rifapentine 450
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifapentine 450 mg daily
Study: 27348211
Drug: Stimulant +
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant + Risperidone
Study: 27348211
Drug: Stimulant +
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant + Placebo
Study: 27348211
Drug: Stimulant only
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant only (baseline)
Study: 17991656
Drug: GOS/lcFOS supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: GOS/lcFOS supplementation (3 times/d with 3 g GOS/lcFOS at a ratio of 9:1)
Study: 113810
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (quasi-control)
Study: 31004676
Drug: Albiglutide liquid
Normalized name: Albiglutide
DrugBank: Albiglutide (DB09043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albiglutide liquid formulation (30 mg for 4 weeks, then 50 mg for 22 weeks)
Study: 31004676
Drug: Albiglutide lyophilized
Normalized name: Albiglutide
DrugBank: Albiglutide (DB09043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albiglutide lyophilized formulation (30 mg for 4 weeks, then 50 mg for 22 weeks)
Study: 31004676
Drug: Albiglutide liquid
Normalized name: Albiglutide
DrugBank: Albiglutide (DB09043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albiglutide liquid formulation
Study: 31004676
Drug: Albiglutide lyophilized
Normalized name: Albiglutide
DrugBank: Albiglutide (DB09043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albiglutide lyophilized formulation
Study: 25029908
Drug: Rituximab maintenance
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab maintenance therapy for 2 years after immunochemotherapy
Study: 23438262
Drug: 60 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mL/kg 0.9% saline bolus
Study: 23438262
Drug: 20 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL/kg 0.9% saline bolus
Study: 21425571
Drug: Ligustrazine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ligustrazine (2 mg/kg, intravenous dripping 30 min before auto-blood collection)
Study: 19436018
Drug: Aspirin (alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (alone or with dipyridamole)
Study: 19436018
Drug: Aspirin (alone)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (alone)
Study: 8872690
Drug: Lidocaine 1.5
Normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1.5 mg/kg (Group LID)
Study: 8872690
Drug: Esmolol 1
Normalized name: esmolol 10 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 1 mg/kg (Group E1)
Study: 8872690
Drug: Esmolol 2
Normalized name: esmolol 20 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 2 mg/kg (Group E2)
Study: 8872690
Drug: Lidocaine 1.5
Normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1.5 mg/kg and Esmolol 1 mg/kg (Group LID-E1)